secwatch.observer — SEC 8-K summary
======================================

Issuer:     ABVC BIOPHARMA, INC. (ABVC)
CIK:        0001173313
Form:       8-K/A
Filed at:   2024-02-29T23:59:59+00:00
Accession:  0001213900-24-018524
Event type: debt
Sentiment:  neutral
Materiality: 0.40
Item codes: 1.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

ABVC BioPharma amends convertible note with Lind: imposes $1 floor conversion price
--------------------------------------------------------------------------------

- Amendment to $1.2M secured convertible note sets conversion floor at $1.00, per Nasdaq requirements.
- If conversion price hits floor, company must make cash payment to Lind based on formula (A-B)*C.
- Lind also received a 5-year warrant to buy 1M shares at $2/share (unchanged from original).
- Note originally issued Nov 17, 2023 for $1M purchase price, $1.2M principal.
- Amendment waives any prior events of default under transaction documents.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024018524/0001213900-24-018524-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1173313/000121390024018524/ea0200878-8ka1_abvcbio.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-018524

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer